Back to Awarded Treatment Trials
Awarded Trial: 02T-140
Ethyl Eicosapentanoic Acid
1000 mg b.i.d.
Secondary Drug Intervention
Duration of Study Period for Each Subject
12 weeks + 40 weeks open-label extension
Extrapyramidal Symptom Rating Scale, PANSS, CGI
Eighty-four subjects were randomized, of whom 77 were included in the analysis. Both the EPA and placebo groups displayed significant baseline to endpoint improvements in Extrapyramidal Symptom Rating Scale dyskinesia scores, but there were no significant between-group differences (p=0.4). Response rates (>=30% improvement in TD symptoms) also did not different significantly between EPA-treated subjects (45%) and placebo-treated subjects (32%) (p=0.6).
Emsley R, Niehaus DJ, Koen L, Oosthuizen PP, Turner HJ, Carey P, van Rensburg SJ, Maritz JS, Murck H. The effects of eicosapentaenoic acid in tardive dyskinesia: a randomized, placebo-controlled trial. Schizophr Res. 2006 May;84(1):112-20. Epub 2006 Apr 24.
Department of Psychiatry
University of Stellenbosch
P.O. Box 19063, Tygerberg
City or Town
State or Province
Zip or Postal Code